Table 1.
Characteristics of epithelial ovarian cancer patients with neoadjuvant chemotherapy.
| Characteristic | All population (n = 27) | Stage III (n = 12) | Stage IV (n = 15) | p value |
|---|---|---|---|---|
| Pre-NACT | ||||
| Median age at diagnosis [IQR], years | 65 [59–70] | 64 [58–65] | 66 [62–74] | 0.249 |
| Median body mass index [IQR], kg/m2 | 26 [23.4–29.7] | 28.2 [22–32.7] | 25.9 [23.4–28.6] | 0.354 |
| Germline BRCA1/2 mutation, n (%) | 1/19 (5) | 1/8 (13) | 0/11 (0) | — |
| Procedures with (+) cytology, n (%) | ||||
| Paracentesis | 15/15 (100) | 10/10 (100) | 5/5 (100) | — |
| Thoracentesis | 6/6 (100) | 0 (0) | 6/6 (100) | — |
| Median volume of paracentesis [IQR], mL | 3000 [1600–5600] | 3500 [1500–6025] | 2600 [1450–4550] | — |
| Median volume of thoracentesis [IQR], mL | 1500 [950–1700] | NA | 1500 [950–1700] | — |
|
| ||||
| NACT∗ | ||||
| Median time from diagnosis to NACT [IQR], days | 26 [19–33] | 29 [20–34] | 25 [15–36] | 0.680 |
| Median NACT cycles, (range) | 3 (3–6) | 3 (3–4) | 4 (3–6) | 0.080 |
| Cycles of NACT, n (%) | ||||
| 3 cycles | 16 (59) | 9 (75) | 7 (47) | — |
| 4 cycles | 7 (26) | 3 (25) | 4 (27) | — |
| 6 cycles† | 4 (15) | 0 (0) | 4 (27) | — |
|
| ||||
| NACT response | ||||
| Hypoalbuminemia‡, n (%) | ||||
| Before NACT | 10 (37) | 5 (41.7) | 5 (33.3) | 0.656 |
| After NACT | 1 (4) | 0 (0.0) | 1 (6.7) | 1.000 |
| Median CA-125 [IQR], U/mL | ||||
| Before NACT | 1077 [500–3317] | 993 [297–3124] | 1168 [707–3460] | 0.661 |
| After NACT§ | 20.4 [11–69] | 21 [12–68] | 19 [8–70] | 0.464 |
| Radiographic response to NACT, n (%) | ||||
| Reduction or resolved, omental caking | 21/24 (88) | 10/11 (91) | 11/13 (85) | — |
| Reduction or resolved, ascites | 21/23 (91) | 10/11 (91) | 11/12 (92) | — |
| Reduction or resolved, pleural effusion | 9/11 (82) | 4/4 (100) | 5/7 (71) | — |
| Reduction or resolved, lesions | 18/21 (86) | 6/9 (67) | 12/13 (92) | — |
∗All patients received taxane/platinum chemotherapy with bevacizumab added in 1 patient. †Four SIV patients received 6 cycles due to physician preference (n = 3) and coronary artery stent placement postponing surgery (n = 1). ‡Serum albumin levels <3.5 g/dL. §Five (42%) SIII and 6 (40%) SIV had abnormal CA-125 levels (>35 U/mL) Post-NACT (range = 36–228 U/mL). IQR: interquartile range; NACT: neoadjuvant chemotherapy.